Trial Profile

Phase III, registrational clinical study of Tumour-lysate-particle-loaded-dendritic-cell-vaccine

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 11 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tumour lysate particle-loaded dendritic cell vaccine Elios Therapeutics (Primary)
Indications Malignant melanoma; Ovarian cancer
Focus Registrational; Therapeutic Use

Most Recent Events

07 Feb 2020 According to an Elios Therapeutics media release, based on the encouraging data from the previous phase 2b study and recent End-of-Phase II discussions with the FDA, the company is planning this registration-enabling study of the TLPLDC vaccine in this high unmet need population of patients with Stage III and IV melanoma.
24 Jul 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com